Dysglycemia in a community sample of people treated for schizophrenia: The Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study

Schizophrenia Research

Volumn 96, Issue 1-3, 2007, Pages 215-222

  Voruganti, L P ^a   Punthakee, Z ^b   Van Lieshout, R J ^a   MacCrimmon, D ^a   Parker, G ^a   Awad, A G ^d   Gerstein, H C ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b Division of Endocrinology and Metabolism   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic drugs; Diabetes; Metabolic risk; Pre diabetes; Schizophrenia

Indexed keywords

GLUCOSE; NEUROLEPTIC AGENT;

ACADEMIC ACHIEVEMENT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CANADA; COMMUNITY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; ETHNICITY; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA;

ADULT; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISABLED PERSONS; EDUCATIONAL STATUS; FEMALE; HUMANS; MALE; MIDDLE AGED; ONTARIO; SCHIZOPHRENIA;

EID: 34848830783     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.07.016     Document Type: Article

References (34)

1. Buckley P.F., Miller D.D., Singer B., et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr. Res. 79 (2005) 281-288
2. Cavazzoni P., Mukhopadhyay N., Carlson C., et al. Retrospective analysis of risk factors in patients with treatment-emergency diabetes during clinical trials of antipsychotic medications. Br. J. Psychiatry 185 Suppl 47 (2004) s94-s101
3. Citrome L., Jaffe A., Levine J., et al. Incidence, prevalence and surveillance for diabetes in New York State Psychiatric Hospitals, 1997-2004. Psychiatr. Serv. 57 (2006) 1132-1139
4. Cohen D., Dekker J.J., Peen J., et al. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur. Neuropsychopharmacol. 16 (2006) 187-194
5. Cohen D., Stolk R.P., Grobbee D.E., et al. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 29 (2006) 786-791
6. Cohn T.A., and Sernyak M.J. Metabolic monitoring for patients treated with antipsychotic medications. Can. J. Psychiatry 51 (2006) 492-501
7. De Hert M., van Winkel R., Van Eyck D., et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 83 (2006) 87-93
8. Dinan T.G. Stress and the genesis of diabetes mellitus in schizophrenia. Br. J. Psychiatry 184 Suppl 47 (2004) s72-s75
9. Dixon L., Weiden P., Delahanty J., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26 (2000) 903-912
10. Goldberg R.W., Kreyenbuhl J.A., Medoff D.R., Dickerson F.B., Wohlheiter K., Fang L.J., Brown C.H., and Dixon L.B. Quality of diabetes care among adults with serious mental illness. Psychiatr. Serv. 58 4 (2007) 536-543
11. Henderson D.C., Nguyen D.D., Copeland P.M., et al. Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risks and mortality: results of a 10-Year naturalistic study. J. Clin. Psychiatry 66 (2005) 1116-1121
12. Hung C., Wu C., and Lin P. Diabetes mellitus in patients with schizophrenia in Taiwan. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 523-527
13. Hux, J., Booth, G., Slaughter, P., et al., 2003. Diabetes in Ontario. ICES Practice Atlas Series. Institute of Clinical Evaluative Sciences www.ices.on.ca/publications/research atlases.
14. Kisely S., Smith M., Lawrence D., Cox M., et al. Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ 13 176(6) (2007) 779-784
15. Lamberti J.S., Costea G.O., Olson D., et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. J. Clin. Psychiatry 66 (2005) 900-906
16. Marder S.R., Essock S.M., Miller A.L., et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatr. 161 (2004) 1334-1349
17. McKibbin C.L., Patterson T.L., Norman G., et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr. Res. 86 (2006) 36-44
18. Meyer J.M., and Nasrallah H.A. Issues surrounding medical care for individuals with schizophrenia: the challenge of dual neglect by patients and the system. In: Meyer J.M., and Nasrallah H.A. (Eds). Medical Illness and Schizophrenia (2003), American Psychiatric Publishing Inc, Washington, DC
19. Meyer J., Loh C., Leckband S.G., et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J. Psychiatr. Pract. 12 (2006) 5-10
20. Morrison V.L. Observation and snowballing: useful tools for research into illicit drug use. Soc. Pharmacol. 2 (1988) 247-271
21. Mukherjee S., Decina P., Bocola V., et al. Diabetes mellitus in schizophrenic patients. Compr. Psychiatry 37 (1996) 68-73
22. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., and Lieberman J.A. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 86 1-3 (2006) 15-22
23. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 19 Suppl 1 (2005) 1-93
24. Newcomer J.W., Nasrallah H.A., and Loebel A.D. The atypical antipsychotic therapy and metabolic issues national survey practice patterns and knowledge of psychiatrists. J. Clin. Psychopharmacol. 24 (2004) S1-S6
25. Philippe A., Vaiva G., and Casadebaig F. Data on diabetes from the French cohort study in schizophrenia. Eur. Psychiatr. 20 (2005) S340-S344
26. Ryan M.C.M., and Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 71 (2002) 239-257
27. Sernyak M.J., Leslie D.L., Alarcon R.D., et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159 (2002) 561-566
28. Sernyak M.J., Gulanski B., Leslie D.L., et al. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J. Clin. Psychiatry 64 (2003) 605-608
29. SPSS Inc. SPSS 14.0 for Windows, Release 14.0.2 (2005), SPSS Inc., Chicago, Illinois
30. Subramaniam M., Chong S.A., and Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can. J. Psychiatry 48 (2003) 345-347
31. Tabata J., Kikuoka M., Kikuoka H., et al. Characteristics of diabetes mellitus in schizophrenic patients. J. Med. Assos. Thail., Suppl. 70 Suppl 2 (1987) 90-93
32. The expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 11 (2003) 3160-3167
33. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am. J. Psychiatry 124 (1968) 978-982
34. Waitzkin L. A survey for unknown diabetics in a mental hospital. I. men under age fifty. Diabetes 15 (1966) 97-104